Achieve Life Sciences Added to Russell 2000 Index, Gaining Exposure to $12.2T Benchmarks
ACHV•Achieve Life Sciences was added to the Russell 2000 Index effective June 26, 2026 as part of the Russell U.S. Indexes reconstitution. The inclusion increases exposure to institutional investors tracking approximately $12.2 trillion in Russell benchmarks and could enhance demand for its late-stage cytisinicline nicotine-dependence therapy.
1. Added to Russell 2000 Index
Achieve Life Sciences was added to the Russell 2000 Index effective June 26, 2026 as part of the annual Russell U.S. Indexes reconstitution process and now joins roughly 2,000 small-cap U.S. equities.
2. Exposure to Institutional Benchmarks
Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. Indexes, meaning inclusion could trigger purchases by index-tracking funds and expand institutional investor interest in Achieve stock.
3. Company Focus and Therapy Pipeline
Achieve is developing cytisinicline as a plant-based treatment for nicotine dependence, with two completed Phase 3 trials and FDA Breakthrough Therapy designation for vaping cessation, positioning it for potential commercialization.
